The production and sales of drugs have become normal, and it is urgent for pharmaceutical companies to accelerate their transformation

Recently, the Liaoyang Municipal Market Supervision and Administration Bureau of Liaoning Province issued an announcement on the cancellation of the "Drug Business License" of Liaoning Taixing Pharmaceutical Chain Co.
, Ltd.
Liaoyang Hongxiang Branch and other enterprises
.
It is worth noting that not long ago, the Liaoning Municipal Market Supervision Administration had just cancelled the "Drug Business License" of Liaoning Fuyuantang Pharmacy Chain Co.
, Ltd.
Liaoyang Jidongyu Branch and other enterprises
.
In this regard, the industry said that it has long been normal for the drug business license to be cancelled
.
On December 6, the Chongqing Municipal Drug Administration, upon application from the company, cancelled the Drug Distribution License of Chongqing Yuxuantang Pharmaceutical Co.
, Ltd.
due to the termination of drug distribution
.
It is worth mentioning that, in addition to the cancellation of the drug business license, the drug registration certificate is not a minority
.
It is understood that since the beginning of this year, the State Drug Administration has issued an announcement to cancel the registration certificate, and there have already been more than 800 drugs
.
For example, on December 9, the website of the State Drug Administration issued an announcement that 210 drug registration certificates were cancelled
.
Including a variety of commonly used drugs, such as chloramphenicol tablets, pain relief tablets, vitamin B1 tablets, vitamin B2 tablets, norfloxacin capsules, aspirin enteric-coated tablets, estazolam tablets, cephalexin tablets, cefradine capsules, etc.

.
On November 15, the State Food and Drug Administration issued an announcement on the cancellation of the registration certificates of 8 types of medicines including Xiaoerfenaminokamin granules (No.
138 of 2021).
After the launch of 8 varieties, such as, aminopyrine tablets, compound aminopyrinyl theophylline tablets, amrinol capsules, aminocamin tablets, bufenac cream, children's compound aspirin tablets, and amphipine tablets, etc.
Evaluation
.
After evaluation, the State Drug Administration has decided to stop the production, sale, and use of the above-mentioned eight varieties in China from today, and cancel the drug registration certificate
.
From the perspective of the industry, this is the general trend caused by the survival of the fittest under the in-depth promotion of the consistency evaluation work
.
Driven by a series of medical reform policies such as centralized procurement, consistency evaluation, and medical insurance control fees, the domestic pharmaceutical market environment is constantly changing, and competition among drugs has become increasingly fierce.
It has become normal for some products that do not have advantages to be eliminated at an accelerated rate.

.
In the future, this wave of cancellation of drug business licenses and registration certificates is expected to continue, and industry concentration will continue to increase
.
The industry believes that in this context, both pharmaceutical companies and pharmaceutical companies must actively adjust their development strategies and accelerate transformation in order to better keep up with policies and industry requirements
.
It is understood that most pharmaceutical companies are already accelerating their transformation in the direction of innovation
.
Statistics show that in recent years, the investment in innovative R&D of local pharmaceutical companies has been continuously increasing
.
Among them, the R&D investment of large-scale enterprises has increased by about 8% annually.
In 2020, the R&D expenses of listed companies will account for more than 6% of sales revenue
.
In addition, the R&D investment of innovative drug industry chain companies in the third quarter of 2021 has also increased by more than 30% year-on-year, reaching 20.
996 billion yuan
.
In the context of accelerated transformation and upgrading of domestic pharmaceutical companies, the industry expects that future pharmaceutical innovation achievements will continue to emerge, and the competitiveness of related companies will continue to increase
.